Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
The addition of camrelizumab to neoadjuvant chemotherapy improves pathological complete response for patients with early or locally advanced triple-negative breast cancer, according to a study ...
Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...
The addition of atezolizumab to standard neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with stages II-III ...
We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...
Dr. Stéphanie Gaillard and Dr. Bill Tew share updates to the evidence-based guideline on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. They highlight recommendations across ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results